Faghihi Sara, Awadi Mohammad Reza, Mousavi Seyyedeh Elaheh, Rezayat Sorkhabadi Seyyed Mahdi, Karboni Mandana, Azarmi Shirzad, Ghaffari Solmaz
Department of Pharmaceutics, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Department of Research and Development, Hakim Pharmaceutical Co, Tehran, Iran.
Adv Pharm Bull. 2022 Jan;12(1):86-92. doi: 10.34172/apb.2022.008. Epub 2020 Sep 8.
To overcome the side effects of repetitive administration of diazepam (Dzp) besidesgaining benefits from sustaining release of the drug, which contributes to patient compliance,we concentrated on designing and preparing Dzp solid lipid nanoparticles (SLNs). Using cholesterol (CHOL), stearic acid (SA), and glycerol monostearate (GMS), SLNswere prepared by high shear homogenization technique coupled with sonication. Polysorbate80 (Tween 80) was used as a nonionic surfactant. After modification of prepared SLNs, particlesize, zeta potential, drug-loading efficiency, morphology, and scanning calorimetry, as well asrelease studies were conducted. To increase the stability of desired particles, freeze-drying bycryoprotectant was carried out. In the final stage, studies were performed by oral (PO)and intraperitoneal (IP) administrations to Wistar male rats. Results indicated that optimized prepared particles were on average 150 nm diameterin spherical shape with 79.06 % loading efficiency and release of more than 85% of the loadeddrug in 24 hours. investigations also illustrated differences in blood distribution of Dzpafter loading this drug into SLNs. Based on the findings, it seems that drug delivery using SLNs could be anopportunity for solving complications of Dzp therapy in the future.
为了克服重复给予地西泮(Dzp)的副作用,同时从药物的缓释中获益,这有助于提高患者的依从性,我们专注于设计和制备Dzp固体脂质纳米粒(SLNs)。使用胆固醇(CHOL)、硬脂酸(SA)和单硬脂酸甘油酯(GMS),通过高剪切均质技术结合超声处理制备了SLNs。聚山梨酯80(吐温80)用作非离子表面活性剂。对制备的SLNs进行修饰后,进行了粒径、zeta电位、载药效率、形态、扫描量热法以及释放研究。为了提高所需颗粒的稳定性,采用冷冻保护剂进行冷冻干燥。在最后阶段,对Wistar雄性大鼠进行了口服(PO)和腹腔注射(IP)给药研究。结果表明,优化制备的颗粒平均直径为150 nm,呈球形,载药效率为79.06%,24小时内释放超过85%的载药。研究还表明,将该药物载入SLNs后,Dzp的血液分布存在差异。基于这些发现,未来使用SLNs进行药物递送似乎是解决Dzp治疗并发症的一个机会。